Table I.
Clinical characteristics of the AML cases
| Patient # | Age/Sex | Diagnosis | Dosage Level |
Karyotype | % Blasts (Absolute Blast Count) |
Response CR/PR/NR/NE |
|---|---|---|---|---|---|---|
| P1 | 61/M | 2° refractory | 3 | 45,XY,−7 | 50% (1,100) |
CR |
| P2 | 26/F | 2° refractory | 3 | 46,XX, −20q |
26% 1,118) |
CR |
| P3 | 36/M | 1° refractory | 4 | 46,XY | 12% (966) |
CR |
| P4 | 20/F | Multi-refractory | 5 | complex | 61% (10,181 |
CR |
| P5 | 47/F | 1° refractory | 5 | complex | 90% (540) |
CR |
| P6 | 62/M | 1° refractory* | 2 | Trisomy 8 | 10% (710) |
PR |
| P7 | 34/M | 1° refractory** | 2 | complex | 29% (1,189) |
PR |
| P8 | 60/F | 1° refractory | 2 | complex | 95% (31,873 |
NR |
| P9 | 63/F | 1° refractory | 2 | 46,XX | 20% (2,284) |
NR |
| P10 | 43/M | 1° refractory | 3 | 46,XY, t(11;19) |
75% (18,120 |
NR |
| P11 | 55/M | Multi-refractory | 4 | 46,XY | 75% (750) |
NR |
| P12 | 41/F | 1° refractory | 4 | 46,XX | 41% (2,530) |
NR |
| P13 | 59/M | 1° refractory | 5 | 46,XY | 55% (6,914) |
NR |
| P14 | 53/F | 1° refractory | 5 | complex | 41% (18,425 |
NR |
| P15 | 69/M | Multi-refractory | 6 | 47,XY,+8 | 32% (403) |
NR |
| P16 | 23/F | 1° refractory | 2 | Inv 8 t(8;8) |
83% (14,757 |
NE |
Patient characteristics are listed above.
#
denotes a death during treatment; 20 refers to AML that occurred in the setting of MDS or chemotherapy for a prior malignancy; M-male; F-female; CR-Complete remission; NR-No response; PR-Partial response; NE-Non-evaluable.